Biosimilars in Gastric Cancer

Gastric cancer, often known as GC, continues to be one of the most common forms of cancer in the world. Its toll in 2020 exceeded one million new cases and positioned it at the fourth spot in terms of worldwide fatalities. Since its inception, substantial study has been carried out to enhance the prognosis of GC therapy. The advancement of GC therapy in the past few years has rendered biosimilars a viable therapeutic option. Comparability testing is a crucial step in the manufacturing of biosimilars to ensure that the finished product meets the safety, efficacy, and quality standards of the reference product. The biosimilar versions of trastuzumab such as Ontruzant (SB3), Trazimera (PF-05280014), Herzuma (CT-P6), Kanjinti (ABP980), etc.. have demonstrated effectiveness in the treatment of GC, making them a competitive substitute for the reference medicine. By including biosimilars into GC therapy regimens, it is possible to enhance patient access to quality care while taking healthcare expenses into account.